Top

Published in:

01-08-2019 | Esophageal Cancer | Thoracic Oncology

Does a Lymph Node-Based Model Predict Clinical Value for Adjuvant Therapy in Squamous Cell Carcinoma of the Esophagus Treated With Upfront Surgery?

Authors: Dana McCloskey, MD, David D. Shersher, MD

Published in: Annals of Surgical Oncology | Issue 8/2019

Excerpt

The management of esophageal cancers is different outside the Western world, where the majority of esophageal cancer histology is squamous cell carcinoma (SCC) and many high-volume centers still use an esophagectomy-first approach. This differs from Western methodology, which is rooted in the landmark 2012 randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) trial, which demonstrated a clear difference in median overall survival of 49.4 versus 24.0 months between neoadjuvant chemoradiotherapy plus surgery and surgery only, respectively.1 The safety and efficacy of the CROSS regimen led to its wide adoption in North America, with neoadjuvant chemoradiotherapy for all esophageal carcinomas and consideration of surgery as trimodality therapy for appropriate candidates. …

Hagen P, Hulshof MCCM, Van Lanschot JJB, Steyerberg EW, Henegouwen MVB, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed

Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, et al. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015;112:597–602.CrossRefPubMed

Murphy MB, Xiao L, Patel VR, Maru DM, Correa AM, Amlashi GF, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variable and survival: the University of Texas MD Anderson Cancer Center experience. Cancer. 2017;123:4106–13.CrossRef

Burt BM, Groth SS, Sada YH, Farjah F, Cornwell L, Sugarbaker DJ, et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer. Ann Surg. 2017;266:297–304.CrossRefPubMed

Wong AT, Shao M, Rineer J, Lee A, Schwartz D, Schreiber D. The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma. Ann Surg. 2017;265:1146–51.CrossRefPubMed

Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, et al. The benefit of chemotherapy in esophageal cancer patients with residual disease after trimodality therapy. Am J Clin Oncol. 2016;39:136–41.CrossRefPubMedPubMedCentral

Gao SJ, Park HS, Corso CD, Rutter CE, Kim AW, Johung KL. Role of adjuvant treatment in esophageal cancer with incidental pathologic node positivity. Ann Thorac Surg. 2017;104:267–74.CrossRefPubMed

Brescia AA, Broderick SR, Crabtree TD, Puri V, Musick JF, Bell JM. Adjuvant therapy for positive nodes after induction therapy and resection of esophageal cancer. Ann Thorac Surg. 2016;101:200–8.CrossRefPubMed

National Comprehensive Cancer Network Guidelines for Esophageal and Esophagogastric Junction Cancer, version 1.2019. Retrieved 27 May 2019 at https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.

10.

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36:2796–803.CrossRefPubMedPubMedCentral

11.

Li Y, Zhao W, Ni J, Zou L, Yang X, Yu W, et al. Predicting the value of adjuvant therapy in esophageal squamous cell carcinoma by combining the total number of examined lymph nodes with the positive lymph node ratio. Ann Surg Oncol. 2019. In press.

Title: Does a Lymph Node-Based Model Predict Clinical Value for Adjuvant Therapy in Squamous Cell Carcinoma of the Esophagus Treated With Upfront Surgery?
Authors: Dana McCloskey, MD
David D. Shersher, MD
Publication date: 01-08-2019
Publisher: Springer International Publishing
Keywords: Esophageal Cancer
Esophagus Resection
Esophageal Cancer
Esophagus Resection
Published in: Annals of Surgical Oncology / Issue 8/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-019-07491-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Does a Lymph Node-Based Model Predict Clinical Value for Adjuvant Therapy in Squamous Cell Carcinoma of the Esophagus Treated With Upfront Surgery?

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2019

The Pelvis-First Approach for Robotic Proctectomy in Patients with Redundant Abdominal Colon

Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma

Clinical Importance of Sputum in the Respiratory Tract as a Predictive Marker of Postoperative Morbidity After Esophagectomy for Esophageal Cancer

Para-aortic Lymphadenectomy for Gynecologic Cancers: Introducing the “Trans-Retro-Peritoneal (TRP) Single-Port Access”

Low Risk of Development of a Regional Recurrence After an Unsuccessful Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

The Sentinel Lymph Node Biopsy Using Indocyanine Green Fluorescence Plus Radioisotope Method Compared With the Radioisotope-Only Method for Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial